CBIO Crescent Biopharma
Crescent Biopharma earnings company data as of 4:45 AM ET 11/1
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | -0.57 | — | — |
| Rev | $357.1K | — | — |
Insider trades
Open-market buys and sales by CBIO's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $30.6M bought by 1 insider
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
Fairmount Funds Management LLC Director, +3 joint filersBuy$12.4M 853,450 shares at $14.50 +31% to stakeTraded Jul 16 Filed Jul 20
-
Fairmount Funds Management LLC Director, +3 joint filersBuy$18.2M 1,360,000 shares at $13.41 +98% to stakeTraded Dec 4, 2025 Filed Dec 8, 2025
Also filed in the last 12 months, not counted as buying or selling: 16 stock grants and 16 sales to cover taxes.
SEC filings
Recent issuer filings from EDGAR, 20 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 424B3 | Filing Doc | ||
| SCHEDULE 13D/A | — | Filing Doc | |
| 424B5 | Filing Doc | ||
| 8-K | 8.01,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 8-K | 2.02 | Filing Doc | |
| 10-Q/A | Filing Doc | ||
| 424B3 | Filing Doc | ||
| 8-K | 5.07 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 424B3 | Filing Doc | ||
| DEFA14A | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.